Free Trial
NASDAQ:AEON

AEON Biopharma 5/14/2024 Earnings Report

AEON Biopharma logo
$0.61 +0.00 (+0.66%)
As of 03:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AEON Biopharma EPS Results

Actual EPS
-$20.16
Consensus EPS
-$22.32
Beat/Miss
Beat by +$2.16
One Year Ago EPS
N/A

AEON Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AEON Biopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

AEON Biopharma's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

AEON Biopharma Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More AEON Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AEON Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AEON Biopharma and other key companies, straight to your email.

About AEON Biopharma

AEON Biopharma (NASDAQ:AEON), a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

View AEON Biopharma Profile

More Earnings Resources from MarketBeat